Compare Gilead Sciences, Inc. (GILD) vs Tilray Brands Inc (TLRY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Tilray Brands Inc — how do they compare? Gilead Sciences, Inc. trades at $134.68 (market cap $163.51B), while Tilray Brands Inc trades at $4.37 (market cap $541.36M). The key difference: Gilead Sciences, Inc. is far larger — about 302× Tilray Brands Inc's market cap, and Gilead Sciences, Inc. pays a 2.49% dividend while Tilray Brands Inc pays none. Which is the better fit depends on your goals.
| GILD | TLRY | |
|---|---|---|
Market Cap | $163.51B | $541.36M |
Sector | Health | Health |
52-Week High | $155.80 | $21.00 |
52-Week Low | $108.22 | $4.31 |
Enterprise Value | $178.05B | $638.50M |
Dividend Yield | 2.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.30, up 2.51% today, with strong technical momentum above key support at $130. The company demonstrates robust fundamentals with a 30.99% net income margin and consistent earnings beats in recent quarters. Recent FDA and EC approvals for Trodelvy in metastatic triple-negative breast cancer highlight growth potential beyond its HIV franchise.
Outlook remains positive with a consensus price target of $152.83 offering 14.6% upside, though risks include patent expirations and competitive pressures. The stock presents a compelling opportunity driven by oncology expansion and strong cash flow generation, supported by overwhelming analyst bullish sentiment.
TLRY trades at $4.36, down 0.57% on the day, amid a bearish technical signal and mixed quarterly earnings. The company reported a net loss of -$2.19 billion for 2025 despite revenue growth to $821 million, with a negative net income margin of -156.67%. Recent developments include medical cannabis expansion in Panama and the acquisition of HelloMD to enhance digital healthcare capabilities.
While low valuation ratios (P/S of 0.55, P/B of 0.35) suggest potential undervaluation, persistent losses and negative cash flow from operations pose significant risks. Analyst sentiment is cautious with a 'Hold' consensus, reflecting concerns over profitability despite growth initiatives. The stock's outlook hinges on achieving sustainable profitability and navigating competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Tilray Brands Inc
Tilray is a Canadian company that grows and sells medical and recreational cannabis. In 2021, Aphria acquired Tilray in a reverse merger and adopted the Tilray name. Most of its sales come from Canada and international medical cannabis exports, while its U.S. business focuses on CBD products and alcohol.
Read more on TLRY →
